Glucocorticoid-induced osteoporosis (OP) is better treated with a synthetic form of the human parathyroid hormone, Teriparatide. This finding was disclosed by a recent study. The study findings were published in the November 2009 issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

It was disclosed by the researchers that patients with OP and treated with Teriparatide for a period of 36 months experienced greater increase in bone mineral density (BMD) and fewer new vertebral fractures than those treated with alendronate.

From Sciencedaily.com:

Results show at 36 months the BMD for lumbar spine was 11% higher than baseline in the teriparatide group compared with 5.3% in the alendronate group. The BMD (teriparatide versus alendronate) for total hip was 5.2% versus 2.7% and 6.3% versus 3.4% for femoral neck. Researchers also observed fewer vertebral fractures in subjects taking teriparatide (1.7%) than those administered alendronate (7.7%). Higher levels of calcium concentrations were noted in the teriparatide group (21%) than in the alendronate group (7%).

“There is a significant number of individuals who are regularly treated with steroids to control inflammation which puts them at risk for developing osteoporosis. A need for therapies that mitigate this side-effect of steroid use and substantially improves bone mass is vital,” commented Dr. Saag. The ACR estimates that diseases commonly treated with (cortico) steroids may affect more than 30 million Americans. “Our research shows that teriparatide is a safe and effective treatment for patients with steroid-induced OA and should be considered as a therapeutic option for those at high risk of bone fracture,” recommended Dr. Saag.

The measures of this research included changes in lumbar spine and hip bone, BMD, changes in bone biomarkers, fracture incidence, and safety. The 36-month, randomized, double-blind, controlled trial, led by Kenneth Saag, M.D., from the University of Alabama, was conducted at 76 centers located in 13 countries.

Tags: alendronate, osteoporosis, steroids, teriparatide

Posted in buy steroids, Steroid Cycles, steroid nation, Steroids and Anabolic Steroids

An existing drug for osteoporosis, Teriparitide, has been found as the first drug to prevent loss of cartilage from osteoarthritis after an incident of joint injury. This drug is also capable of regenerating a portion of cartilage lost because of osteoarthritis.

These findings were reported at the annual meeting of the American Society for Bone and Mineral Research in Denver.

From Sciencedaily.com:

Cartilage can become damaged by many kinds of injury and by mechanical stresses that come with age. Over time, damaged cartilage deteriorates to cause osteoarthritis (OA), with its attendant joint inflammation and pain. Currently available drugs like steroids or non-steroidal anti-inflammatory agents (e.g. Advil, Aleve) reduce pain but do not address the loss of cartilage behind the osteoarthritis, which is projected to afflict more than 50 million Americans by 2020.

Cartilage forms the sponge-like, shock-absorbing layers that keep the impact of running and jumping and lifting from grinding bones against each other in joints. The cell type at the heart of osteoarthritis is the chondrocyte, the cartilage-producing cell responsible for maintaining the integrity of joint cartilage.

This study was funded by the National Institutes of Health and conducted by Randy Rosier, M.D., Ph.D., professor within the Department of Orthopaedics and Rehabilitation at the University of Rochester Medical Center in collaboration with Erik Sampson, Todd O’Brien, Di Chen, Susan Bukata, J. Edward Puzas, Regis O’Keefe and Michael Zuscik within the Department of Orthopaedics and by Hani Awad in the Department of Biomedical Engineering at the University of Rochester Medical Center.

Tags: joint injury, osteoporosis, steroids, teriparitide

Posted in buy steroids, Steroid Cycles, steroid nation, Steroids and Anabolic Steroids

A human trial of a new osteoporosis drug is about to be initiated by Endocrinologists at the University of Pittsburgh School of Medicine and UPMC. The trial is expected to offer significant relief to osteoporosis patients suffering from weakened bones.

Principal investigator Mara J. Horwitz, M.D., an assistant Professor of Medicine in the Division of Endocrinology and Metabolism, Pitt School of Medicine, and a practicing metabolic bone specialist at UPMC, said that 105 participants will be randomly assigned to receive either teriparitide, FDA-approved drug, or an experimental agent known as parathyroid hormone-related protein (PTHrP).

From Sciencedaily.com:

Another kind of agent works on the other end of the bone metabolism see-saw: it promotes the creation of new bone. Teriparitide, a form of naturally occurring parathyroid hormone, currently is the only FDA-approved anabolic or bone-building agent in the United States. The experimental drug PTHrP, another protein made naturally by the body, also is an anabolic agent and appears to be unique in its ability to stimulate bone formation without simultaneously increasing bone breakdown. Both drugs are given as daily injections.

“When we studied PTHrP several years ago in small numbers of postmenopausal women with osteoporosis, we found that bone density increased by nearly 5 percent after only three months of treatment,” said senior investigator Andrew F. Stewart, M.D., professor and chief of the Division of Endocrinology and Metabolism, Department of Medicine, Pitt School of Medicine. “And even at the highest doses, the side effects were negligible.”

In findings published online last week in the Journal of Clinical Endocrinology and Metabolism, Drs. Horwitz and Stewart and their colleagues identified the maximum tolerable dose and therapeutic window of PTHrP. In this study, they were also able to show that PTHrP, at the tolerable doses, stimulated bone formation after only three weeks of treatment.

This research was funded by the National Institutes of Health and the University of Pittsburgh Clinical Translational Sciences Award.

Tags: anabolic, osteoporosis, PTHrP, teriparitide

Posted in buy steroids, Steroid Cycles, steroid nation, Steroids and Anabolic Steroids

An osteoporosis drug may prove its addition worth by preventing cartilage loss arising due to osteoarthritis after a joint injury, as per an early study presented at the annual meeting of the American Society for Bone and Mineral Research in Denver.

Even though presently available drugs such as steroids or non-steroidal anti-inflammatory agents (e.g. Advil, Aleve) are effective for minimizing the level of associated pain yet they are ineffective for completely addressing loss of cartilage due to osteoarthritis that is believed to afflict more than 50 million Americans by 2020.

From News-Medical.Net:

Parathyroid hormone (PTH), known as teriparatide in drug form, has emerged as a major player in the maintenance and healing of bone, and the race is on to design new applications for it. Past studies have established that PTH prevents chondrocytes from undergoing maturation, and stimulates their proliferation, preserving larger pools of cartilage cells in the joint. Signaling molecules like PTH have their effect in the body by interacting with specifically shaped proteins on the cell surfaces called receptors. PTH docks into its receptors, like a ship coming into port, which changes the shape of the dock such that biochemical signals are sent.

The authors of the current study observed that chondrocytes within injured and degenerating cartilage have more PTH type 1 receptors on their surfaces. This makes them especially sensitive to the PTH signal that prevents harmful chondrocyte maturation into bone in the joint cartilage. Thus, PTH therapy should increase the cartilage supply exactly where cartilage loss is causing disease.

Physicians are often left clueless when it comes to restoration of cartilage in patients suffering from osteoarthritis, as per Randy Rosier, M.D., Ph.D., professor within the Department of Orthopedics and Rehabilitation at the University of Rochester Medical Center.

Tags: Advil, Aleve, cartilage loss, osteoarthritis, osteoporosis, osteoporosis drug, steroids

Posted in buy steroids, Steroid Cycles, steroid nation, Steroids and Anabolic Steroids

An existing drug for osteoporosis has been hailed as the first ever found for preventing loss of cartilage from osteoarthritis post joint injury besides being useful in regenerating some part of cartilage lost due to osteoarthritis.

This finding was presented on September 12, 2009 at the annual meeting of the American Society for Bone and Mineral Research in Denver.

From Sciencedaily.com:

Cartilage can become damaged by many kinds of injury and by mechanical stresses that come with age. Over time, damaged cartilage deteriorates to cause osteoarthritis (OA), with its attendant joint inflammation and pain. Currently available drugs like steroids or non-steroidal anti-inflammatory agents (e.g. Advil, Aleve) reduce pain but do not address the loss of cartilage behind the osteoarthritis, which is projected to afflict more than 50 million Americans by 2020.

Cartilage forms the sponge-like, shock-absorbing layers that keep the impact of running and jumping and lifting from grinding bones against each other in joints. The cell type at the heart of osteoarthritis is the chondrocyte, the cartilage-producing cell responsible for maintaining the integrity of joint cartilage.

Randy Rosier, M.D., Ph.D., professor within the Department of Orthopedics and Rehabilitation at the University of Rochester Medical Center, said physicians are presently left with no way to restore cartilage in patients who have lost it to osteoarthritis but the study results suggest that cartilage degeneration can be inhibited and the volume of cartilage in diseased joints be improved, at least in mice.

Tags: osteoarthritis, osteoporosis, steroids

Posted in buy steroids, Steroid Cycles, steroid nation, Steroids and Anabolic Steroids

Glucocorticoid-induced osteoporosis (OP) is now treatable with Teriparatide, which is a synthetic form of the human parathyroid hormone, according to a recent study.

It was found by the researchers that patients with glucocorticoid-induced osteoporosis and treated with teriparatide for a period of 36 months had a significant increase in BMD (bone mineral density) and fewer new vertebral fractures than those treated with alendronate.

From Sciencedaily.com:

Glucocorticoids are steroid hormones that are naturally produced in the body or synthetically created compounds (drugs) used to reduce inflammation. These steroid drugs are used to control inflammation in patients with such autoimmune diseases as rheumatoid arthritis, systemic lupus erythematosus, and Crohn’s disease as well as inflammatory conditions such as asthma. Glucocorticoid-induced osteoporosis occurs when patients taking steroid medications such as prednisone, prednisolone, dexamethasone, and cortisone exhibit reduced bone mass and bone strength.

This 36-month, randomized, double-blind, controlled trial, led by Kenneth Saag, M.D., from the University of Alabama, was conducted at 76 centers located in 13 countries. A total of 428 patients between the ages of 22-89 with confirmed OP who had received greater than 5 mg/day of prednisone or equivalent for more than 3 months preceding screening were included. Research measures included changes in lumbar spine and hip bone, BMD, changes in bone biomarkers, fracture incidence, and safety.

The findings of this study were published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

Tags: alendronate, osteoporosis, steroid, steroid hormones, teriparatide

Posted in buy steroids, Steroid Cycles, steroid nation, Steroids and Anabolic Steroids, Steroids in Sports

The quality of life for HIV-patients may have improved due to introduction of highly active antiretroviral therapy (HAART) but that has increased the risk of long-term negative disorders, namely osteoporosis.

Osteoporosis is a multifactorial ailment that is characterized by a consistent minimization in body bone mass and its mechanical resistance. Increased propensity to bone fractures is a common symptom with individuals suffering from this medical complication.

From News-Medical.Net:

Now, a study has been published in the Spanish review Enfermedades Infecciosas y Microbiología Clínica [Infectious Diseases and Clinical Microbiology] showing the increase in prevalence of this disorder in HIV-1 infected patients.

The principal investigator of the study, José Manuel Olmos, clarifies to SINC that: “As soon as Highly Active Antiretroviral Therapy was introduced, which we call HAART, this infection was transformed into a chronic disease with an acceptable quality of life in the developed countries”.

There are multiple reasons that explain the propensity to osteoporosis in those patients who have the virus. Some are related to the HIV-1 infection itself, such as the lymphocyte activity, the release of cytokines that stimulate bone absorption, hypogonadism (a disorder where the reproductive organs do not function), Vitamin D deficit, malnutrition or low level of physical activity. Other reasons depend on the treatment patients receive with corticosteroid and antiretroviral medicines.

According to the authors, “for the moment, it does not seem that osteoporotic fractures represent a significant problem. However, as the patient gets older a reduction in their quality of life may occur.

The authors noted that a bone densitometry scan is required to be performed each and every time there is a data pertaining to hypogonadism, treated with steroids for chronic ailment or a past history of osteoporosis induced fractures with an aim to improve patient’s progress.

Tags: body bone mass, bone densitometry scan, HAART, highly active antiretroviral therapy, hypogonadism, osteoporosis, steroids

Posted in bodybuilding, buy steroids, Steroid Cycles, Steroids and Anabolic Steroids

According to findings of a recent study that was published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), glucocorticoid-induced osteoporosis (OP) is easily treatable with Teriparatide, a synthetic form of the human parathyroid hormone.

Glucocorticoids are steroid hormones, which are produced naturally in the body and can be termed as synthetically created compounds meant for the purpose of reducing inflammation. These steroid drugs are used for controlling inflammation in patients suffering with ailments such as rheumatoid arthritis, systemic lupus erythematosus, asthma, and Crohn’s disease.

From News-Medical.Net:

“There is a significant number of individuals who are regularly treated with steroids to control inflammation which puts them at risk for developing osteoporosis. A need for therapies that mitigate this side-effect of steroid use and substantially improves bone mass is vital,” commented Dr. Saag. The ACR estimates that diseases commonly treated with (cortico)steroids may affect more than 30 million Americans. “Our research shows that teriparatide is a safe and effective treatment for patients with steroid-induced OA and should be considered as a therapeutic option for those at high risk of bone fracture,” recommended Dr. Saag.

Kenneth Saag, M.D., from the University of Alabama, led this 36-month, randomized, double-blind, controlled trial, and recommended that teriparatide is an effective treatment option for patients with steroid-induced OA.

Tags: osteoporosis, steroid, Steroid drugs, steroid hormones, steroids, teriparatide

Posted in buy steroids, Steroid Cycles, steroid nation, Steroids and Anabolic Steroids

Glucocorticoid-induced osteoporosis (OP) is now very much treatable with Teriparatide, a synthetic form of the human parathyroid hormone, as per a recent study.

The involved researchers found that patients with glucocorticoid-induced osteoporosis and administered with teriparatide for a period of 36 months had a greater increase in bone mineral density apart from fewer new vertebral fractures than those treated with alendronate.

The study findings were published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR). The 36-month randomized, double-blind, and controlled trial was conducted at 76 centers located in 13 countries and led by Kenneth Saag, M.D., from the University of Alabama.

From News-Medical.Net:

Study participants were randomly assigned to receive injectable teriparatide (20 μg/day) plus oral placebo (150 subjects) or oral alendronate (10 mg/day) plus injectable placebo (144 subjects). Supplements of calcium (1,000 mg/day) and vitamin D (800 IU/day) were provided to all study participants. Subjects kept a daily journal to record their steroid use.

Results show at 36 months the BMD for lumbar spine was 11% higher than baseline in the teriparatide group compared with 5.3% in the alendronate group. The BMD (teriparatide versus alendronate) for total hip was 5.2% versus 2.7% and 6.3% versus 3.4% for femoral neck. Researchers also observed fewer vertebral fractures in subjects taking teriparatide (1.7%) than those administered alendronate (7.7%). Higher levels of calcium concentrations were noted in the teriparatide group (21%) than in the alendronate group (7%).

Dr. Saag commented that there are a considerable number of individuals treated regularly with steroids for controlling inflammation that puts them at risk for developing osteoporosis and teriparatide is a safe and effective treatment for patients with steroid-induced osteoporosis.

Tags: alendronate, glucocorticoid, osteoporosis, steroid, steroid use, teriparatide

Posted in buy steroids, Steroid Cycles, steroid nation, Steroids and Anabolic Steroids

An existing osteoporosis drug can prove to be an effective treatment option for preventing cartilage loss from osteoarthritis after a joint injury, as per an early study presented today at the annual meeting of the American Society for Bone and Mineral Research in Denver.

It is important to note that the presently available drugs such as steroids or non-steroidal anti-inflammatory agents (e.g. Advil, Aleve) can be good enough to minimize pain but are not capable of addressing cartilage loss behind osteoarthritis that is believed to afflict more than 50 million Americans by 2020.

From News-Medical.Net:

Parathyroid hormone (PTH), known as teriparatide in drug form, has emerged as a major player in the maintenance and healing of bone, and the race is on to design new applications for it. Past studies have established that PTH prevents chondrocytes from undergoing maturation, and stimulates their proliferation, preserving larger pools of cartilage cells in the joint. Signaling molecules like PTH have their effect in the body by interacting with specifically shaped proteins on the cell surfaces called receptors. PTH docks into its receptors, like a ship coming into port, which changes the shape of the dock such that biochemical signals are sent.

The authors of the current study observed that chondrocytes within injured and degenerating cartilage have more PTH type 1 receptors on their surfaces. This makes them especially sensitive to the PTH signal that prevents harmful chondrocyte maturation into bone in the joint cartilage. Thus, PTH therapy should increase the cartilage supply exactly where cartilage loss is causing disease.

According to Randy Rosier, M.D., Ph.D., professor within the Department of Orthopedics and Rehabilitation at the University of Rochester Medical Center, physicians are left with no answer when it comes to bringing back cartilage in patients who have lost the battle to osteoarthritis.

The results of this study, suggesting a slight restoration of cartilage, can prove helpful for physicians treating patients with osteoarthritis.

Tags: Advil, Aleve, cartilage loss, osteoarthritis, osteoporosis, osteoporosis drug, steroids

Posted in buy steroids, Steroid Cycles, steroid nation, Steroids and Anabolic Steroids